1. Atrx loss as a promising screening tool for the identification of diffuse midline glioma subtype, H3K27/MAPKinase co-altered.
- Author
-
Tauziède-Espariat, Arnault, Castel, David, Ajlil, Yassine, Auffret, Lucie, Appay, Romain, Mariet, Cassandra, Hasty, Lauren, Métais, Alice, Chrétien, Fabrice, Grill, Jacques, and Varlet, Pascale
- Subjects
GLIOMAS ,CENTRAL nervous system tumors ,NUCLEOTIDE sequencing ,STEREOTAXIC techniques - Abstract
This document, published in Acta Neuropathologica Communications, discusses the identification of a subtype of diffuse midline glioma (DMG) called H3K27/MAPKinase co-altered. The study analyzes a cohort of 182 pediatric and adult cases of DMG, H3K27-altered and identifies 30 tumors with a loss of ATRX expression. The authors provide clinical, histopathological, and molecular data on these tumors and suggest that the loss of ATRX expression may be a potential diagnostic tool for identifying DMG, H3K27/MAPK co-altered. The study highlights the distinct features of this subtype and emphasizes the importance of integrating clinical, radiological, histopathological, and molecular results for an accurate diagnosis. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF